Results 21 to 30 of about 596,620 (345)

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

New England Journal of Medicine, 2017
Background In a phase 1 trial, axicabtagene ciloleucel (axi‐cel), an autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy, showed efficacy in patients with refractory large B‐cell lymphoma after the failure of conventional therapy. Methods
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Stiff, J. Friedberg, I. Flinn, A. Goy, B. Hill, Mitchell R. Smith, A. Deol, U. Farooq, P. Mcsweeney, J. Muñoz, I. Avivi, J. Castro, J. Westin, J. Chavez, A. Ghobadi, K. Komanduri, R. Levy, E. Jacobsen, T. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, David D. Chang, J. Wiezorek, W. Go   +39 more
semanticscholar   +1 more source

Transformation of follicular lymphoma [PDF]

Best Practice & Research Clinical Haematology, 2011
Histological transformation of follicular lymphoma (FL) to a more aggressive non-Hodgkin's lymphomas is a pivotal event in the natural history of FL and is associated with poor outcome. While commonly observed in clinical practice and despite multiple studies designed to address its pathogenesis, the biology of this process represents an enigma.
Izidore S, Lossos, Randy D, Gascoyne
openaire   +2 more sources

Gastric Follicular Lymphomas Presenting as Subepithelial Tumors: Two Cases

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2018
Follicular lymphoma is the most common form of low-grade B cell lymphoma. Follicular lymphoma occurs predominantly at lymph node sites and rarely in the gastrointestinal tract. Rare gastrointestinal follicular lymphoma is most commonly found in the small
Hyeong Jin Kim, Cheol Woong Choi, Su Bum Park, Su Jin Kim   +3 more
doaj   +1 more source

Smad1 Expression in Follicular Lymphoma [PDF]

Journal of Pathology and Translational Medicine, 2015
Background: Follicular lymphomas present with various immunohistologic patterns. The immunohistochemical markers used in the diagnosis of follicular lymphoma show variable degrees of sensitivity and specificity, and thus, additional germinal center ...
Jai Hyang Go
doaj   +1 more source

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial [PDF]

, 2019
Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular ...
Angrilli, F., Barbui, A. M., Benedetti, F., Billio, A., Boccomini, C., Bruna, R., Castellino, C., Ciceri, F., Corradini, P., Devizzi, L., Di Raimondo, F., Dondi, A., Gini, G., Gueli, A., Ladetto, M., Lanza, F., Liberati, A. M., Mantoan, B., Massimo Gianni, A., Musso, M., Narni, F., Parvis, G., Passera, R., Patti, C., Perrone, T., Pulsoni, A., Rambaldi, A., Rossini, F., Rota-Scalabrini, D., Semenzato, G., Stelitano, C., Tarella, C., Tucci, A., Zallio, F., Zoli, V.   +34 more
core   +4 more sources

Peripheral T-Cell Lymphomas of the T Follicular Helper Type: Clinical, Pathological, and Genetic Attributes

Hemato, 2022
Follicular helper T-cell (TFH) lymphomas comprise a unique group of T-cell lymphomas that represent neoplastic proliferations of follicular helper T-cells and share genetic, immunophenotypic, morphologic, and clinical features.
Karthik A. Ganapathi, Kristin H. Karner, Madhu P. Menon   +2 more
doaj   +1 more source

Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles

Haematologica, 2011
Background According to the current World Health Organization Classification of Lymphoid Tumours, follicular lymphoma is subclassified into three grades according to the number of centroblasts.
Heike Horn, Christopher Schmelter, Ellen Leich, Itziar Salaverria, Tiemo Katzenberger, M. Michaela Ott, Jörg Kalla, Monica Romero, Reiner Siebert, Andreas Rosenwald, German Ott   +10 more
doaj   +1 more source

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]

, 2017
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha, A Chanan-Khan, A Davies, A Prica, AR Rezvani, B Bonavida, B Coiffier, B Coiffier, B Coiffier, B Eichhorst, B Eichhorst, BS Kahl, C Dartigeas, C Gisselbrecht, C Müller, C Taverna, CS Tam, D Daydé, D Müller, D Rossi, David G. Maloney, DG Maloney, DG Maloney, DG Maloney, DW Scott, E Bachy, E Deconinck, E Hoster, E Kimby, E Vellenga, E Zucca, EA Chong, EJ Soini, FB Hagemeister, FT Awan, G Köhler, G Lenz, G Martinelli, G Poeta Del, G Poeta Del, G Salles, G Salles, GA Salles, Gilles Salles, GJ Weiner, GJ Weiner, H Blasco, H Hochster, H Schulz, H Tilly, HC Kluin-Nelemans, HM Blommestein, HR Junlén, International CLL-IPI Working Group, J Banchereau, J Hiraga, J Hornberger, J Hornberger, J Li, JA Ray, JA Woyach, JC Byrd, JC Byrd, JM Foran, JM Vose, JO Armitage, Joerg Maurer, JP Leonard, K Fischer, K Fischer, K Fischer, K Tobinai, K Tobinai, KA Foon, KA Foon, KM Ardeshna, KM Johnston, L Li, L Tran, L Vidal, LA Torre, LD Piro, LM Nadler, M Adena, M Dreyling, M Dreyling, M Federico, M Feuring-Buske, M Hallek, M Hallek, M Herold, M Jermann, M Pfreundschuh, M Pfreundschuh, M Pfreundschuh, M Tout, MA Dimopoulos, MA Lopez-Olivo, Martin Barrett, MB Regazzi, MD Danese, ME Reff, ME Williams, MH Oers van, MH Oers van, Michael Wenger, MJ Keating, MJ Rummel, MS Czuczman, MS Czuczman, Nancy Valente, NL Berinstein, O Mandrik, OW Press, P Abrisqueta, P Boffetta, P Boross, P Colombat, P Feugier, P Hillmen, P McLaughlin, P Thompson, PV Beum, Q Chen, Q Chen, R Forstpointner, R Forstpointner, R Foà, R Griffiths, R Marcus, R Marcus, RA Miller, RI Griffiths, RI Griffiths, RL Elstrom, Robin Foà, S Assouline, S Cang, S Khor, S Maury, SG Fisher, SM Jaglowski, SM O’Brien, Susan O’Brien, T Igarashi, T Kewalramani, T Robak, TA Davis, TA Davis, TJ Kipps, TM Habermann, U Jaeger, U Jäger, UJ Mey, V Goede, V Ivanov, V Minard-Colin, V Ribrag, W Hiddemann, W Wierda, XC Badoux, Y Oki   +161 more
core   +2 more sources

Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features

Haematologica, 2013
Nodal marginal zone lymphoma is a poorly defined entity in the World Health Organization classification, based largely on criteria of exclusion and the diagnosis often remains subjective.
Oscar Krijgsman, Patricia Gonzalez, Olga Balagué Ponz, Margaretha G.M. Roemer, Stefanie Slot, Annegien Broeks, Linde Braaf, Ron M. Kerkhoven, Freek Bot, Krijn van Groningen, Max Beijert, Bauke Ylstra, Daphne de Jong   +12 more
doaj   +1 more source

TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma

Clinical Cancer Research, 2020
Purpose: T-cell immunoglobulin and ITIM domain (TIGIT), a member of the immune checkpoint family, is important in normal T-cell biology. However, the phenotypical profile and clinical relevance of TIGIT in follicular lymphoma is largely unknown ...
Zhi-Zhang Yang, H. Kim, Hongyan Wu, S. Jalali, Xinyi Tang, J. Krull, W. Ding, A. Novak, S. Ansell   +8 more
semanticscholar   +1 more source